Cagrilintide for weight loss: what the trials actually show

What did @mashunjohnson141 actually say?

The creator mentioned injecting what sounds like 2.5mg of cagrilintide that morning, then showed their first meal at 3:07 PM, preemptively defending themselves: "I know I supposed to eat." That self-aware disclaimer is actually the most clinically interesting part of this video.

To be clear about what was and wasn't said: there were no dosing instructions, no disease claims, and no explicit weight loss promises. This is someone narrating their own experience with a research-phase peptide. The hashtag "justforresearchpurposes" is a fig leaf, but the content itself is relatively low-key, just a person showing delayed eating while on a compound they're calling "cag."

The rough audio makes the exact dose unclear, but 2.5mg aligns with doses used in published cagrilintide trials. That detail matters for context, not as a recommendation.

Does the science back this up?

Cagrilintide is a long-acting amylin analogue developed by Novo Nordisk. The appetite suppression this creator is implicitly showing, eating once at 3 PM, is actually consistent with how amylin analogues work. But calling it validated by science requires some nuance.

Amylin is a pancreatic hormone that slows gastric emptying and reduces food intake. Cagrilintide mimics this effect with a longer half-life. In the SCALE-like CagriSema trials combining cagrilintide with semaglutide, Lau et al. (2021, The Lancet) reported up to 15.6% mean body weight loss at 26 weeks with combined therapy, with appetite suppression being a primary driver.

What the science does not support is the idea that skipping meals is a feature rather than a side effect worth managing. Prolonged low caloric intake on amylin-based therapies can undercut lean mass retention. The spontaneous meal skipping shown here is real, but presenting it casually without flagging protein intake or muscle loss risk is an incomplete picture.

What did they get wrong (or right)?

Credit where it's due: the creator didn't claim cagrilintide cures anything, didn't give dosing advice, and was honest that they know skipping meals isn't ideal. That puts this video above a lot of peptide content on TikTok.

What's missing is the risk side of prolonged appetite suppression. Research from Enebo et al. (2021, The Lancet) on cagrilintide monotherapy noted nausea and reduced energy intake as common effects. Eating one meal late in the day while on an amylin analogue raises legitimate questions about whether that meal is delivering adequate protein and micronutrients.

The creator also appears to be using a compounded or research-grade version of cagrilintide. Cagrilintide is not FDA-approved as a standalone agent. The purity, concentration, and stability of research peptides sourced outside clinical trials are genuinely unknown quantities. That's not a minor footnote. It's a real gap in what viewers should understand before treating this video as a how-to.

What should you actually know?

Cagrilintide is not approved by the FDA as a standalone drug. The most advanced clinical data comes from the CagriSema combination program, where it is paired with semaglutide. Using it solo, sourced from a research peptide supplier, puts you outside any validated safety framework.

The appetite suppression shown in this video is pharmacologically real and consistent with amylin receptor activation. That's not the problem. The problem is that significant appetite reduction without deliberate nutritional planning can lead to muscle loss, micronutrient deficiency, and rebound eating. Studies on GLP-1 and amylin-based therapies consistently show that protein intake has to be actively managed, it doesn't happen automatically.

If you're considering any peptide-based therapy for weight management, the question isn't just "does it suppress appetite?" It's "what happens to body composition, metabolic health, and long-term weight maintenance when the peptide is discontinued?" Those answers require a clinician, not a TikTok comment section.